BioCryst Pharmaceuticals Valuation

Is BCRX * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BCRX * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BCRX * (MX$155) is trading below our estimate of fair value (MX$914.98)

Significantly Below Fair Value: BCRX * is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BCRX *?

Key metric: As BCRX * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BCRX *. This is calculated by dividing BCRX *'s market cap by their current revenue.
What is BCRX *'s PS Ratio?
PS Ratio	3.8x
Sales	US$412.58m
Market Cap	US$1.58b

BCRX * key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.1x
Enterprise Value/EBITDA	-65.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BCRX *'s PS Ratio compare to its peers?

The above table shows the PS ratio for BCRX * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	10.6x
LAB B Genomma Lab Internacional. de	1.4x	9.9%	Mex$25.3b
NRIX Nurix Therapeutics	26.8x	39.1%	US$1.5b
A214450 PharmaResearch	6.9x	24.2%	₩2.2t
688276 Changchun BCHT Biotechnology	7.1x	26.9%	CN¥11.4b
BCRX * BioCryst Pharmaceuticals	3.8x	15.3%	Mex$1.6b

Price-To-Sales vs Peers: BCRX * is good value based on its Price-To-Sales Ratio (3.8x) compared to the peer average (10.6x).

Price to Sales Ratio vs Industry

How does BCRX *'s PS Ratio compare vs other companies in the Global Biotechs Industry?

272 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	n/a	0%
BCRX * BioCryst Pharmaceuticals	3.8x	15.3%	US$1.58b

272 Companies		Estimated Growth	Market Cap
Industry Avg.	n/a	0%
BCRX * BioCryst Pharmaceuticals	3.8x	72.8%	US$1.58b

No more companies

Price-To-Sales vs Industry: BCRX * is good value based on its Price-To-Sales Ratio (3.8x) compared to the Global Biotechs industry average (9.3x).

Price to Sales Ratio vs Fair Ratio

What is BCRX *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BCRX * PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BCRX *'s Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BCRX * forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	n/a	Mex$299.49 0%	43.2%	Mex$606.32	Mex$161.69	n/a	11
Dec ’25	n/a	Mex$294.41 0%	43.3%	Mex$603.45	Mex$160.92	n/a	11
Nov ’25	n/a	Mex$280.77 0%	44.0%	Mex$582.73	Mex$135.97	n/a	11
Oct ’25	n/a	Mex$280.62 0%	44.0%	Mex$582.42	Mex$135.90	n/a	11
Sep ’25	Mex$170.00	Mex$280.62 +65.1%	44.0%	Mex$582.42	Mex$135.90	n/a	11
Aug ’25	n/a	Mex$249.03 0%	46.7%	Mex$533.64	Mex$106.73	n/a	11
Jul ’25	n/a	Mex$236.31 0%	46.7%	Mex$506.39	Mex$101.28	n/a	11
Jun ’25	n/a	Mex$236.31 0%	46.7%	Mex$506.39	Mex$101.28	n/a	11
May ’25	n/a	Mex$232.60 0%	46.7%	Mex$505.00	Mex$101.00	n/a	11
Apr ’25	n/a	Mex$232.60 0%	46.7%	Mex$505.00	Mex$101.00	n/a	11
Mar ’25	Mex$98.86	Mex$237.35 +140.1%	46.7%	Mex$515.30	Mex$103.06	n/a	11
Feb ’25	n/a	Mex$237.35 0%	46.7%	Mex$515.30	Mex$103.06	n/a	11
Jan ’25	n/a	Mex$241.06 0%	46.2%	Mex$513.23	Mex$102.65	n/a	11
Dec ’24	n/a	Mex$241.06 0%	46.2%	Mex$513.23	Mex$102.65	n/a	11
Nov ’24	n/a	Mex$274.41 0%	46.2%	Mex$541.61	Mex$144.43	n/a	10
Oct ’24	n/a	Mex$260.32 0%	46.2%	Mex$513.78	Mex$137.01	n/a	10
Sep ’24	n/a	Mex$258.14 0%	47.1%	Mex$512.86	Mex$136.76	Mex$170.00	10
Aug ’24	n/a	Mex$258.02 0%	48.1%	Mex$514.32	Mex$137.15	n/a	10
Jul ’24	Mex$120.00	Mex$259.38 +116.2%	47.2%	Mex$513.62	Mex$136.97	n/a	10
Jun ’24	n/a	Mex$265.88 0%	45.8%	Mex$533.38	Mex$142.23	n/a	11
May ’24	n/a	Mex$268.01 0%	45.5%	Mex$539.29	Mex$143.81	n/a	11
Apr ’24	n/a	Mex$283.83 0%	41.7%	Mex$550.97	Mex$146.92	n/a	11
Mar ’24	n/a	Mex$283.83 0%	41.7%	Mex$550.97	Mex$146.92	Mex$98.86	11
Feb ’24	n/a	Mex$322.95 0%	36.2%	Mex$580.16	Mex$193.39	n/a	10
Jan ’24	n/a	Mex$331.91 0%	35.6%	Mex$592.70	Mex$197.57	n/a	10
Dec ’23	n/a	Mex$346.41 0%	31.8%	Mex$590.47	Mex$236.19	n/a	10

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.